Yarvitan

RSS

Withdrawn

This medicine's authorisation has been withdrawn

mitratapide
MedicineVeterinaryWithdrawn

Danish is available via eTranslation, the European Commission's machine translation service.

Translate to Danish | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for this product has been withdrawn at the request of the marketing authorisation holder.

español (ES) (256.72 KB - PDF)

Vis

čeština (CS) (393.52 KB - PDF)

Vis

dansk (DA) (256.17 KB - PDF)

Vis

Deutsch (DE) (257.38 KB - PDF)

Vis

eesti (ET) (255.5 KB - PDF)

Vis

ελληνικά (EL) (454.41 KB - PDF)

Vis

français (FR) (257.52 KB - PDF)

Vis

italiano (IT) (256.43 KB - PDF)

Vis

latviešu (LV) (399.71 KB - PDF)

Vis

lietuvių (LT) (373.07 KB - PDF)

Vis

magyar (HU) (384.35 KB - PDF)

Vis

Nederlands (NL) (256.77 KB - PDF)

Vis

polski (PL) (403.94 KB - PDF)

Vis

português (PT) (257.16 KB - PDF)

Vis

slovenčina (SK) (389.05 KB - PDF)

Vis

slovenščina (SL) (380.7 KB - PDF)

Vis

suomi (FI) (255.8 KB - PDF)

Vis

svenska (SV) (256.06 KB - PDF)

Vis

Product information

български (BG) (876.69 KB - PDF)

Vis

español (ES) (368.06 KB - PDF)

Vis

čeština (CS) (682.61 KB - PDF)

Vis

dansk (DA) (413.04 KB - PDF)

Vis

Deutsch (DE) (363.22 KB - PDF)

Vis

eesti (ET) (360.22 KB - PDF)

Vis

ελληνικά (EL) (926.55 KB - PDF)

Vis

français (FR) (369.55 KB - PDF)

Vis

italiano (IT) (358.34 KB - PDF)

Vis

latviešu (LV) (723.79 KB - PDF)

Vis

lietuvių (LT) (500.34 KB - PDF)

Vis

magyar (HU) (667.24 KB - PDF)

Vis

Malti (MT) (707.97 KB - PDF)

Vis

Nederlands (NL) (359.17 KB - PDF)

Vis

polski (PL) (707.86 KB - PDF)

Vis

português (PT) (369.01 KB - PDF)

Vis

română (RO) (511.36 KB - PDF)

Vis

slovenčina (SK) (679.07 KB - PDF)

Vis

slovenščina (SL) (667.27 KB - PDF)

Vis

suomi (FI) (355.26 KB - PDF)

Vis

svenska (SV) (366.58 KB - PDF)

Vis
Latest procedure affecting product information:II/0003
20/10/2008

български (BG) (312.24 KB - PDF)

Vis

español (ES) (232.03 KB - PDF)

Vis

čeština (CS) (307.25 KB - PDF)

Vis

dansk (DA) (233.01 KB - PDF)

Vis

Deutsch (DE) (235.26 KB - PDF)

Vis

eesti (ET) (231.11 KB - PDF)

Vis

ελληνικά (EL) (308.87 KB - PDF)

Vis

français (FR) (231.59 KB - PDF)

Vis

italiano (IT) (231.31 KB - PDF)

Vis

latviešu (LV) (309.08 KB - PDF)

Vis

lietuvių (LT) (262.26 KB - PDF)

Vis

magyar (HU) (304.77 KB - PDF)

Vis

Malti (MT) (309.64 KB - PDF)

Vis

Nederlands (NL) (234.5 KB - PDF)

Vis

polski (PL) (274.42 KB - PDF)

Vis

português (PT) (231.94 KB - PDF)

Vis

română (RO) (295.75 KB - PDF)

Vis

slovenčina (SK) (306.51 KB - PDF)

Vis

slovenščina (SL) (304.86 KB - PDF)

Vis

suomi (FI) (231.26 KB - PDF)

Vis

svenska (SV) (231.79 KB - PDF)

Vis

Product details

Name of medicine
Yarvitan
Active substance
mitratapide
International non-proprietary name (INN) or common name
mitratapide
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) code
QA08AB90

Pharmacotherapeutic group

Antiobesity preparations, excl. diet products

Therapeutic indication

As an aid in the management of overweight and obesity in adult dogs. To be used as part of an overall weight management programme which also includes appropriate dietary changes. Introducing appropriate lifestyle changes (e.g. increased exercise), in conjunction with this weight management programme, may provide additional benefits.

Authorisation details

EMA product number
EMEA/V/C/000113
Marketing authorisation holder
Janssen Pharmaceutica N.V.

Turnhoutseweg 30
B-2340 Beerse
Belgium

Marketing authorisation issued
14/11/2006
Revision
3

Assessment history

This page was last updated on

Share this page